ATE390938T1 - Topische anwendung eines nf-kb decoys zur behandlung atopischer dermatitis - Google Patents

Topische anwendung eines nf-kb decoys zur behandlung atopischer dermatitis

Info

Publication number
ATE390938T1
ATE390938T1 AT02711351T AT02711351T ATE390938T1 AT E390938 T1 ATE390938 T1 AT E390938T1 AT 02711351 T AT02711351 T AT 02711351T AT 02711351 T AT02711351 T AT 02711351T AT E390938 T1 ATE390938 T1 AT E390938T1
Authority
AT
Austria
Prior art keywords
decoy
stat
atopic dermatitis
treatment
topical use
Prior art date
Application number
AT02711351T
Other languages
German (de)
English (en)
Inventor
Ryuichi Morishita
Motokuni Aoki
Toshio Ogihara
Yasufumi Kaneda
Hiroshige Nakamura
Original Assignee
Anges Mg Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anges Mg Inc filed Critical Anges Mg Inc
Application granted granted Critical
Publication of ATE390938T1 publication Critical patent/ATE390938T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02711351T 2001-02-20 2002-02-06 Topische anwendung eines nf-kb decoys zur behandlung atopischer dermatitis ATE390938T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001044350 2001-02-20

Publications (1)

Publication Number Publication Date
ATE390938T1 true ATE390938T1 (de) 2008-04-15

Family

ID=18906362

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02711351T ATE390938T1 (de) 2001-02-20 2002-02-06 Topische anwendung eines nf-kb decoys zur behandlung atopischer dermatitis

Country Status (11)

Country Link
US (2) US9012417B2 (cg-RX-API-DMAC7.html)
EP (2) EP1362600B1 (cg-RX-API-DMAC7.html)
JP (2) JP3778357B2 (cg-RX-API-DMAC7.html)
AT (1) ATE390938T1 (cg-RX-API-DMAC7.html)
CY (1) CY1108165T1 (cg-RX-API-DMAC7.html)
DE (1) DE60225899T2 (cg-RX-API-DMAC7.html)
DK (1) DK1362600T3 (cg-RX-API-DMAC7.html)
ES (1) ES2307733T3 (cg-RX-API-DMAC7.html)
PT (1) PT1362600E (cg-RX-API-DMAC7.html)
TW (1) TWI308492B (cg-RX-API-DMAC7.html)
WO (1) WO2002066070A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT732929E (pt) * 1993-10-29 2008-08-26 Brigham & Womens Hospital Utilização terapêutica de ''engodos'' de elementos cis in vivo
TWI308492B (cg-RX-API-DMAC7.html) * 2001-02-20 2009-04-11 Anges Mg Inc
DE10148886A1 (de) * 2001-10-04 2003-04-30 Avontec Gmbh Inhibition von STAT-1
US20070066935A1 (en) * 2003-05-09 2007-03-22 Ryuichi Morishita Needleless syringe having medical agent accomodated therein
AU2003252493A1 (en) * 2003-07-09 2005-01-28 Anges Mg, Inc. Pharmaceutical composition containing decoy and method of using the same
US20070293447A1 (en) * 2003-08-29 2007-12-20 Yasuo Kunugiza Gene Therapy for Skin Disorders Using Needleless Syringes
JP2007512845A (ja) * 2003-12-02 2007-05-24 アネシバ・インコーポレイテッド Ｎｆ−κｂオリゴヌクレオチドデコイ分子
US8034619B2 (en) * 2003-12-19 2011-10-11 University Of Cincinnati Polyamides for nucleic acid delivery
WO2006034433A2 (en) * 2004-09-21 2006-03-30 Anesiva, Inc. Delivery of polynucleotides
US8067384B2 (en) 2004-10-22 2011-11-29 Anges Mg, Inc. Chimera (double) decoy
US20090214630A1 (en) * 2005-05-10 2009-08-27 Warren Strober Compositions and Methods for the Treatment of Inflammatory Bowel Disease Utilizing NF-KappaB Decoy Polynucleotides
US20060258604A1 (en) * 2005-05-10 2006-11-16 Warren Strober Compositions and methods for the treatment of inflammatory bowel disease utilizing NF-kappaB decoy polynucleotides
EP1892293A4 (en) * 2005-06-06 2008-12-10 Anges Mg Inc TRANSCRIPTION FACTOR DECOY
US20100035793A1 (en) * 2005-07-27 2010-02-11 Cheh Peng Lim Modulators
US20100167390A1 (en) * 2005-12-22 2010-07-01 Toshohiro Nakajima Novel Oligonucleotide and NF-kB Decoy Comprising the Same
WO2007071069A1 (en) * 2005-12-22 2007-06-28 Institut De Cardiologie De Montreal Transcription factor decoy oligodeoxynucleotides having multiple cis elements
JP4602298B2 (ja) * 2006-08-31 2010-12-22 ホソカワミクロン株式会社 医薬製剤
WO2008099906A1 (ja) 2007-02-16 2008-08-21 Anges Mg, Inc. 歯周病、及び外科手術による歯槽骨欠損の治療剤
US20080249044A1 (en) * 2007-04-03 2008-10-09 Masaya Tanaka Nucleic acid external skin formulation
HRP20150759T1 (hr) 2007-05-11 2015-08-14 Adynxx, Inc. Ekspresija gena i bolovi
WO2009119836A1 (ja) * 2008-03-28 2009-10-01 アンジェスＭｇ株式会社 転写因子デコイを有効成分とする外用剤組成物
PT2846839T (pt) 2012-05-10 2019-05-29 Adynxx Inc Formulações para a administração de ingredientes ativos
BR112017002629A2 (pt) 2014-08-15 2018-02-20 Adynxx, Inc. decoys de oligonucleotídeo para o tratamento de dor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2361756A (en) * 1942-03-31 1944-10-31 George W Fiero Ointments and the like
JPS56135416A (en) * 1980-03-27 1981-10-22 Mitsubishi Chem Ind Ltd Pharmaceutical preparation for skin
US4301145A (en) * 1980-07-28 1981-11-17 Cestari Joseph E Antiseptic skin cream
US6150090A (en) 1986-01-09 2000-11-21 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
JPH05331066A (ja) * 1992-05-25 1993-12-14 Toko Yakuhin Kogyo Kk 尋常性ざ瘡治療用組成物
PT732929E (pt) * 1993-10-29 2008-08-26 Brigham & Womens Hospital Utilização terapêutica de ''engodos'' de elementos cis in vivo
US6399376B1 (en) * 1993-11-05 2002-06-04 Isis Pharmaceuticals, Inc. Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions
CA2203566C (en) * 1994-10-24 2001-10-23 Yuko Hosokawa Percutaneously administration preparation
ES2285712T3 (es) 1995-05-12 2007-11-16 Anges Mg, Inc. Medicamento para la terapia y profilaxis de varias enfermedades relacionadas con nf-kappa b.
JPH11507245A (ja) * 1995-11-21 1999-06-29 アイシーエヌ・ファーマシューティカルズ・インコーポレイテッド Ｉｌ―８およびｉｌ―８受容体に対するアンチセンスオリゴヌクレオチドによる睡瘍増殖の阻害
CA2294988C (en) * 1997-07-01 2015-11-24 Isis Pharmaceuticals Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
JP2001055331A (ja) * 1999-06-11 2001-02-27 Toyama Chem Co Ltd アトピー性皮膚炎治療剤
WO2001057204A1 (en) * 2000-02-02 2001-08-09 Yasufumi Kaneda Virus envelope vector for gene transfer
DE10049549A1 (de) * 2000-10-06 2002-05-02 Markus Hecker Modulation der Transkription pro-inflammatorischer Genprodukte
TWI308492B (cg-RX-API-DMAC7.html) 2001-02-20 2009-04-11 Anges Mg Inc
WO2003063911A1 (en) * 2002-02-01 2003-08-07 Anges Mg, Inc. Decoy-containing pharmaceutical compositions and method of using the same
JP4971609B2 (ja) 2004-08-27 2012-07-11 アンジェスＭｇ株式会社 核酸皮膚外用製剤
JP2006111591A (ja) 2004-10-15 2006-04-27 Anges Mg Inc 核酸医薬を標的特異的に細胞内送達するための製剤

Also Published As

Publication number Publication date
PT1362600E (pt) 2008-07-09
EP1690544B1 (en) 2017-09-13
DK1362600T3 (da) 2008-07-28
TWI308492B (cg-RX-API-DMAC7.html) 2009-04-11
JP2009102428A (ja) 2009-05-14
JPWO2002066070A1 (ja) 2004-06-17
US9012417B2 (en) 2015-04-21
EP1690544A3 (en) 2012-03-07
EP1362600A4 (en) 2005-09-21
EP1690544A2 (en) 2006-08-16
DE60225899D1 (de) 2008-05-15
ES2307733T3 (es) 2008-12-01
WO2002066070A1 (fr) 2002-08-29
US20090105183A1 (en) 2009-04-23
EP1362600A1 (en) 2003-11-19
JP3778357B2 (ja) 2006-05-24
DE60225899T2 (de) 2009-04-09
EP1362600B1 (en) 2008-04-02
US20040162251A1 (en) 2004-08-19
CY1108165T1 (el) 2014-02-12
JP4987022B2 (ja) 2012-07-25

Similar Documents

Publication Publication Date Title
ATE390938T1 (de) Topische anwendung eines nf-kb decoys zur behandlung atopischer dermatitis
WO2002043652A3 (en) Anti-proliferative drugs
ATE267798T1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
ITMI20041550A1 (it) Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide
DK1289517T3 (da) Farmaceutiske sammensætninger indeholdende cannabidiolderivater
ATE393221T1 (de) Gegen bakterielle 16s und 23s rrnas gerichtete ungeladene antisense oligonukleotide und deren verwendungen
EP1549767A4 (en) MODULATION OF EXPRESSION OF FORKHEAD BOX O1A
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
WO2001048190A3 (en) Therapeutic uses of lna-modified oligonucleotides
BR0107565A (pt) Formas de dosagem de benzimidazol substituìdo e método de emprego das mesmas
EP1251126A3 (en) Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
ATE332136T1 (de) Mittel, wie nikotinamide oder cadpr zur behandlung von hautkrankheiten
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
ATE307625T1 (de) Wirkstoffabgabesysteme zur behandlung von gefässerkrankungen
MX9602973A (es) Uso de un antagonista de bradiquinina en una composicion, cosmetica, farmaceutica o dermatologica y la composicion obtenida.
AR001790A1 (es) Formulaciones para parches transdermicos que sirven para el tratamiento de condiciones modeladas de receptores muscarinicos
WO2003026563A3 (en) Conjugated anti-psychotic drugs and uses thereof
HUP0200152A2 (hu) KQT1 csatornák gátlóinak alkalmazása parazita férgek és ektoparaziták által okozott betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
DK1343472T3 (da) Thixotropisk næsespray
WO1999056666A8 (en) The treatment of sexual dysfunction in certain patient groups
DE60027127D1 (de) Verwendung von Polyaminosäurederivaten zur Behandlung von Seborrhoe und verwandten Hautstörungen
ATE384133T1 (de) Retinolsäure-rezeptor beta-2 und gentherapievektoren für die behandlung von neurologischen erkrankungen
EP2250887A3 (en) Use of non-antibacterial tetracycline analog CMT-1002 and formulations thereof for the treatment of bacterial exotoxins
BR0115881A (pt) Emprego de compostos ciclohexanona substituìdos de 6-dimetilaminometil-1-fenil para a terapia da incontinência urinária
BR0115880A (pt) Emprego de compostos ciclohexanona de 6-dimetilaminometila-1-fenil para o tratamento da incontinência urinária

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1362600

Country of ref document: EP